Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient ...

Now, researchers in a lab at the University of Minnesota, using a drug called CD200AR-L, have developed their own vaccine to ...

The molecule is also being tested in over 100 vaccine clinical trials. Rising QS-21 demand from the pharmaceutical industry ...

Scientists at Sanaria and Seattle Children's Research Institute's Center for Global Infectious Disease Research (CGIDR) have unveiled a groundbreaking malaria vaccine, Sanaria® PfSPZ-LARC2 Vaccine, ...